BCL2L1 and Thrombocytopenia: Although these therapeutic approaches remain an attractive strategy to induce PCa cell death the ability to drive cancer specific kill from such treatment combinations remains a challenge and concerns with regard to on-target treatment related toxicity persist, namely thrombocytopenia for BCLXL and cardiotoxicity with MCL1.6